File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Re-evaluation of α-interferon treatment of chronic hepatitis B using polymerase chain reaction

TitleRe-evaluation of α-interferon treatment of chronic hepatitis B using polymerase chain reaction
Authors
Issue Date1993
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
Journal Of Hepatology, 1993, v. 17 n. 2, p. 208-214 How to Cite?
AbstractTo re-evaluate the efficacy of 3 treatment trials involving 272 Chinese patients with chronic hepatitis B virus infection, serial serum samples were tested from 60 patients treated with α-interferon with or without prednisone priming and 12 control patients, who were negative for hepatitis B virus deoxyribonucleic acid using dot-blot hybridization. Serial samples were tested using nested polymerase chain reaction with primer sets chosen from the surface and core antigen coding regions. The 19 patients who did not show persistent serological change remained hepatitis B virus deoxyribonucleic acid positive using the polymerase chain reaction assay. Three of the 4 patients (75%) who lost hepatitis B surface antigen and 9 of 51 (17.6%) who lost hepatitis B e antigen became negative from 0 to 60 months after the e-seroconversion. All patients negative for the polymerase chain reaction assay had normal transaminase levels. Pooling the 3 trials together, 11 of 188 (5.9%) treated patients and 1 of 84 (1.2%) control patients became hepatitis B virus deoxyribonucleic acid negative. The difference was not statistically significant. As assayed by the polymerase chain reaction assay, patients who were treated with α-interferon with or without steroid priming and lost hepatitis B e antigen within 12 months were more likely to subsequently lose the virus completely from the serum (11 of 33) than those who lost hepatitis B e antigen after 12 months (none of 13; p = 0.029).
Persistent Identifierhttp://hdl.handle.net/10722/161989
ISSN
2015 Impact Factor: 10.59
2015 SCImago Journal Rankings: 4.570
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChung, HTen_US
dc.contributor.authorLok, ASFen_US
dc.contributor.authorLai, CLen_US
dc.date.accessioned2012-09-05T05:16:29Z-
dc.date.available2012-09-05T05:16:29Z-
dc.date.issued1993en_US
dc.identifier.citationJournal Of Hepatology, 1993, v. 17 n. 2, p. 208-214en_US
dc.identifier.issn0168-8278en_US
dc.identifier.urihttp://hdl.handle.net/10722/161989-
dc.description.abstractTo re-evaluate the efficacy of 3 treatment trials involving 272 Chinese patients with chronic hepatitis B virus infection, serial serum samples were tested from 60 patients treated with α-interferon with or without prednisone priming and 12 control patients, who were negative for hepatitis B virus deoxyribonucleic acid using dot-blot hybridization. Serial samples were tested using nested polymerase chain reaction with primer sets chosen from the surface and core antigen coding regions. The 19 patients who did not show persistent serological change remained hepatitis B virus deoxyribonucleic acid positive using the polymerase chain reaction assay. Three of the 4 patients (75%) who lost hepatitis B surface antigen and 9 of 51 (17.6%) who lost hepatitis B e antigen became negative from 0 to 60 months after the e-seroconversion. All patients negative for the polymerase chain reaction assay had normal transaminase levels. Pooling the 3 trials together, 11 of 188 (5.9%) treated patients and 1 of 84 (1.2%) control patients became hepatitis B virus deoxyribonucleic acid negative. The difference was not statistically significant. As assayed by the polymerase chain reaction assay, patients who were treated with α-interferon with or without steroid priming and lost hepatitis B e antigen within 12 months were more likely to subsequently lose the virus completely from the serum (11 of 33) than those who lost hepatitis B e antigen after 12 months (none of 13; p = 0.029).en_US
dc.languageengen_US
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhepen_US
dc.relation.ispartofJournal of Hepatologyen_US
dc.subject.meshBase Sequenceen_US
dc.subject.meshChronic Diseaseen_US
dc.subject.meshDna, Viral - Analysisen_US
dc.subject.meshHepatitis B - Immunology - Therapyen_US
dc.subject.meshHepatitis B Surface Antigens - Blooden_US
dc.subject.meshHepatitis B Virus - Isolation & Purificationen_US
dc.subject.meshHumansen_US
dc.subject.meshInterferon-Alpha - Therapeutic Useen_US
dc.subject.meshMolecular Sequence Dataen_US
dc.subject.meshNucleic Acid Hybridizationen_US
dc.subject.meshPolymerase Chain Reactionen_US
dc.subject.meshPrednisone - Therapeutic Useen_US
dc.titleRe-evaluation of α-interferon treatment of chronic hepatitis B using polymerase chain reactionen_US
dc.typeArticleen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/S0168-8278(05)80040-6en_US
dc.identifier.pmid8445234-
dc.identifier.scopuseid_2-s2.0-0027398418en_US
dc.identifier.volume17en_US
dc.identifier.issue2en_US
dc.identifier.spage208en_US
dc.identifier.epage214en_US
dc.identifier.isiWOS:A1993KQ78400013-
dc.publisher.placeNetherlandsen_US
dc.identifier.scopusauthoridChung, HT=36797189000en_US
dc.identifier.scopusauthoridLok, ASF=35379868500en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats